NCT01412528

Brief Summary

Today a variety of diagnostic tools to detect allergenic agents are available such as skin tests, provocation tests and blood tests. Due to its high sensitivity and low costs the skin prick test is the most commonly used test to identify allergies in patients. By using this kind of skin test, up to 25 different agents can be tested in parallel, rendering the skin prick test a cheap, easy-to-handle and rapid diagnostic tool. However, as research proceeds, new tools appear with the intention to make future applications even more convenient -for both, the patient and the physician. For that purpose the development of the so called "Easyprick" Allergen Test System is under way, consisting of a foil that carries ready-to-use, allergen-soaked sponges which can easily be applied to the skin after pricking. Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. In order to control variability and to achieve consistency and reproducibility for optimal safety and sensitivity/specificity, it is essential to standardize the amount of allergen used in prick tests. The present study aims to standardize eight allergen extracts by using this method. Standardized extracts will then be applied in the Easyprick Allergen Test System which will be evaluated and compared to the conventional prick test in a second study.

  • Trial with medicinal product

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Aug 2009

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2009

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

April 28, 2010

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2011

Completed
7 months until next milestone

First Posted

Study publicly available on registry

August 9, 2011

Completed
Last Updated

August 9, 2011

Status Verified

January 1, 2011

Enrollment Period

1.4 years

First QC Date

April 28, 2010

Last Update Submit

August 8, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Wheal size

    15 minutes after skin prick test with a serial dilution of an allergen extracts, sizes of provoked wheals will be measured according to allergen standardization procedure.

Study Arms (1)

Eight different allergens will be standardized in this study

OTHER
Other: Allergen extracts

Interventions

Eight different allergens will be standardized in this study

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old,
  • a positive clinical history for inhalant allergy to at least one of the allergens to be tested,
  • at least one positive prick test (mean wheal diameter = 3mm) when tested with already standardized extracts of the allergens under investigation.
  • a mean wheal size of = 7mm2 obtained in a prick test with histamine dihydrochloride (10mg/ml).
  • Written informed consent

You may not qualify if:

  • history of systemic reactions to allergens,
  • severe diseases influencing the results of the present study by discretion of the investigator,
  • immunotherapy with an allergen preparation known to interfere with the allergens under investigation during the past two years,
  • skin lesions in the skin test areas
  • pregnancy or nursing,
  • treatment with prohibited concomitant medications (antihistamines, corticosteroids, anti-depressants, neuroleptics or specific immunotherapy)
  • alcohol or drug abuse,
  • impaired in understanding nature, meaning and the scope of the study or are incapable of giving written informed consent,
  • Participation in another clinical trial within the last 30 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Trials Center

Zurich, Switzerland

Location

MeSH Terms

Conditions

Hypersensitivity

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Officials

  • 01 Studienregister MasterAdmins

    UniversitaetsSpital Zuerich

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 28, 2010

First Posted

August 9, 2011

Study Start

August 1, 2009

Primary Completion

January 1, 2011

Study Completion

January 1, 2011

Last Updated

August 9, 2011

Record last verified: 2011-01

Locations